Dr. Ravi Salgia from University of Chicago describes which patients with advanced NSCLC he seeks molecular marker testing on, and the particular markers he prioritizes.

[powerpress]

Dr. Geoffrey Oxnard, Dana Farber Cancer Institute, discusses the issue of patients or payers objecting to repeat biopsies.

[powerpress]

Dr. Lecia Sequist of Massachusetts General Hospital gives her view on more widespread availability of new mutation tests.

[powerpress]

Dr. Karen Reckamp from City of Hope Cancer Center in Duarte, CA describes which patients with advanced NSCLC she seeks molecular marker testing on, and the particular markers she prioritizes.

[powerpress]

Dr. Geoffrey Oxnard conveys a central theme that the benefits of molecular oncology and optimal application of targeted therapies are dependent on a change in collecting tissue that works to obtain far more tissue than was historically required.

[powerpress]

Dr. Heather Wakelee from Stanford University expresses her practice pattern for patients with advanced non-small cell lung cancer who would need a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

[powerpress]

Dr. Bob Doebele from the University of Colorado reviews which molecular markers have the strongest evidence to support routine testing, and which patients with advanced non-small cell lung cancer he favors molecular testing for. 

[powerpress]

Dr. David Spigel, Sarah Cannon Cancer Center, reviews which patients with lung cancer he feels should undergo molecular testing, as well as describing the potential value of immediate, reflex testing for molecular targets.

[powerpress]

Here's part 5 of our Santa Monica program on Molecular Markers in Advanced NSCLC, closing in on the end of the activity.  In this podcast, my friend Dr.

Here's the next installment of the panel discussion on molecular markers from the webinar in Santa Monica with Drs. Charlie Rudin, Alice Shaw, David Spigel, and Glen Goss.  We continued our animated discussion on the promise as well as the pitfalls of broadening the use of molecular markers in routine practice of managing patients with advanced NSCLC.